ABSTRACT: Due to the development of antibiotic resistance in microorganisms, antimicrobial peptides from natural sources have attracted attention in recent times. Several antimicrobial peptides have been isolated from a wide range of animal sources, particularly snake venoms. Naja naja venom showed antibacterial as well as direct and indirect hemolytic activities, and an antibacterial peptide was purified through gel permeation and ion exchange chromatography. Its molecular mass was 2491Da, which was determined using Matrix Assisted Laser Desorption/IonizationTime-of-Flight (MALDI-TOF) mass spectrometry and the amino acids sequence of the N-terminus was DEQSTHGAYVWKL. The purified peptide showed potent antibacterial activity against Gram-negative and Gram-positive bacterial strains like Escherichia coli, Pseudomonas aeruginosa and Vibrio cholerae, and Staphylococcus aureus, Enterococcus faecalis, Streptococcus pneumoniae, Streptococcus pyogenes, Bacillus subtilis, respectively. The most potent activity was towards Gramnegative bacteria. Activity was retained at concentrations as low as 100µg/ml. Minimum inhibitory concentrations (MIC; in μg) of Naja Antibacterial Peptide (NAP) and known antibiotics against Gram-positive and Gram-negative bacteria were determined using microdilution susceptibility test in sterile 96-well microdilution plates. However, the peptide did not show direct or indirect hemolytic activity.
INTRODUCTION
Antimicrobial Peptides (AMPs) are an extremely diverse group of small proteins that have in common a native antimicrobial activity. The existence of AMPs has been known for several decades, but only recently has their function been recognized as essential to the animal immune response. They participate primarily in the innate immune system and are used as a first line of immune defense by many organisms, including plants, insects, bacteria and vertebrates (9) . These molecules are peptides with a high level of basic and hydrophobic amino acids. They present a broad antimicrobial spectrum against bacteria, fungi or parasites, by acting through insertion into the cell membrane or bind to receptors. Therefore, these molecules are promising for the development of antibiotics especially for the treatment against multiresistant microorganisms (7, 19) . For this reason, significant commercial interest and effort have been made to develop cationic peptides as potential antimicrobial therapeutics. Recent studies have clarified that antimicrobial peptides are an important component of the innate defense of all species (5).
More than 700 AMPs have already been identified in living species like bacteria, fungi, amphibians, insects, reptiles and mammals (10) . In the last years, several AMPs have been found in different venoms from different animals and are traditionally linked to defense mechanisms (6) . Snake venoms are rich sources of pharmacologically active polypeptides and proteins. Peptides from snake venoms are of biological interest as a potential source of active compounds. These molecules could act as (or be used as a prototype for) (i) therapeutic agents; (ii) research tools for the diagnosis of several diseases; (iii) basic research about physiological and pathological processes (22) . Snake venom has been established to show bactericidal activity (8) and the action of its proteins on E. coli has been extensively studied (23) . The action of snake venom AMPs on clinical bacterial strains has also been reported (24) . Venoms from 30 different snake species were tested using disk diffusion test for antibacterial activity (21) . In the present study, the isolation and characterization of a peptide from N. naja venom was reported as well as its inhibitory activity against different bacterial strains. 
MATERIALS AND METHODS

Materials
Indian cobra (Naja naja) venom was purchased from Irulla Snake-Catchers Association, Chennai, Tamil Nadu, India. CM-Sephadex C- 25 
Protein Estimation
Protein concentration was determined according to the method of Lowery et al. (16) using BSA as standard.
Sephadex G-75 Column Chromatography
Lyophilized N. naja venom (300mg in 1ml) was dissolved in 10mM potassium phosphate buffer, pH 7.4, and centrifuged at 5000g for 5min. The supernatant was applied to a column (0.8cm X 120cm) of Sephadex G-75 equilibrated and eluted with the same buffer at 20 o C. The fractions from the column were eluted at a flow rate of 20ml/h and 2ml fractions were collected. Protein elution was monitored at 280nm using a Shimadzu spectrophotometer (1601A). Alternate tubes were assayed for antibacterial activity. Fractions presenting activity were individually pooled, desalted, lyophilized and stored at -4 o C.
CM-Sephadex C-25 Column Chromatography
Peak III (90mg in 3ml equilibrating buffer) from Sephadex G-75 column was loaded onto a CM-Sephadex C-25 column (1.2cm X 40cm) equilibrated with 10mM potassium phosphate buffer, pH 7.4. The column was eluted by a stepwise gradient of potassium phosphate buffer (10mM-150mM) and NaCl (0.01M-1M). Fractions were eluted at 20 o C at a flow rate of 25ml/h and 2.5ml fractions were collected.
Protein elution was monitored at 280nm using a Shimadzu spectrophotometer.
Fractions presenting antibacterial activity were pooled, desalted, lyophilized and stored at -4 o C.
Sephadex G-25 Column Chromatography
Peak IV (36mg in 1ml of equilibrating buffer) from CM-Sephadex C-25 column was loaded onto a Sephadex G-25 column (0.75cm X 60cm) equilibrated with 10mM potassium phosphate buffer, pH 7.4. The fractions from the column were eluted at a flow rate of 20ml/h and 2ml fractions were collected. Protein elution was monitored at 280nm using a Shimadzu spectrophotometer (1601A). Alternate tubes were assayed for antibacterial activity. Fractions presenting activity were individually pooled, desalted, lyophilized and stored at -4 o C.
High-Performance Liquid Chromatography
Purified NAP was subjected to Reverse Phase-High-Performance Liquid Chromatography (RP-HPLC) on Vydac-C 18 (5µm, 0.21cm X 25cm) column. The column was first equilibrated with Solvent A (0.1% Trifluoroacetic Acid -TFA) until the base line monitored at 220nm was stable. The peptide was then injected into the column. Elution was carried out with a linear gradient (0%-100%) of Solvent B (70% Acetonitrile in 0.1% TFA). Peptide elution was monitored at 220nm.
Mass Spectrometry
The molecular mass of NAP was determined using MALDI-TOF mass spectrometry (Voyager Spec # 1 MC) in positive ionization mode. α-Cyano-4-hydroxycinnamic acid was used as MALDI matrix.
N-Terminal Sequencing
The terminal sequencing of NAP was carried out in a fully automated Shimadzu protein sequencer (PSQ-1) system that employs Edman's degradation reaction for sequential separation of N-terminal amino acids. 
Hemolytic Activity
Direct and indirect hemolytic activities were assayed as described by Boman and Kalletta (4). The substrate for direct hemolytic activity was prepared by suspending 
Statistics
For all experiments, results were expressed as the mean ± SEM of at least 3 independent experiments. 
RESULTS
Purification of NAP
Naja naja venom (300mg) subjected to gel permeation chromatography on a Sephadex G-75 column resolved into three protein peaks. The antibacterial activity of the whole venom and its fraction is shown in Table 1 . When all the peaks were screened for antibacterial activity, only peak III showed activity (Fig. 1) . The peak III from the Sephadex G-75 fraction was pooled, concentrated and desalted using Sephadex G-10 column. The pooled peak III fraction was further resolved into four peaks on CM-Sephadex C-25 column by applying NaCl gradient (Fig. 2) . Only peak IV exhibited potent antibacterial activity and contributed to 73.98% of the total activity loaded, and 4.5% of the protein loaded on CM-Sephadex C-25 column was recovered in this antibacterial fraction. The antibacterial activity of this fraction was increased by 6-fold compared to the whole venom activity. Further, peak IV from the CM-Sephadex C-25 fraction was pooled, concentrated and loaded onto Sephadex G-25 column. On fractionation, the peptide components resolved into two peaks, which were designated as peak A and peak B (Fig. 3) . Peak B showed significant antibacterial activity and increased by 10-fold, compared to the whole venom activity.
The homogeneity of the antibacterial peptide was examined by RP-HPLC using C18
column. The elution buffer contained 0.1% TFA and was eluted with acetonitrile gradient. NAP eluted as single symmetrical sharp peak with a retention time of 43.6min (Fig. 4) . The molecular mass determined by MALDI-TOF mass spectrometry was 2491Da (Fig. 5) . The NAP N-terminal sequence analysis indicated the following 13 amino acids sequence: DEQSTHGAYVWKL. All these data clearly established that the antibacterial peptide was purified to homogeneity. Sephadex G-25 column (0.75cm X 60cm) was eluted with 10mM potassium phosphate buffer, pH 7.4, at a flow rate of 20ml/h and 2ml fractions were collected.
Antibacterial Activity of NAP
The protein elution profile (─) was monitored at 280nm in a spectrophotometer.
Fractions showing antibacterial activity (dotted line) were pooled for further analysis. (3, 7, 19) . Some of the first reports about antibacterial activity in snake venoms were in 1948 and in 1968, involving Elapidae and Viperidae venoms (8, 25) . Venoms from snakes of the Viperidae family present antimicrobial activity against Sarcina species, while in the Elapidae family, a lytic factor or cytotoxin composed of a basic low-molecular-weight protein was found in Naja species, and Hemachatus haemachatus was shown to have antibacterial activity. They were able to disrupt S.
aureus and E. coli phospholipid membranes, respectively (23, 25) . In the present study, NAP displayed higher inhibitory activity against Gram-negative bacteria like E. The peptide dissolves divalent cations that are essential for outer membrane and consequently distorts the outer membrane bilayer (20) . This allows access to the cytoplasmic membrane where peptides channel formation has been proposed to occur (13) . It is an intermediate step in the uptake of peptides into the cytoplasm, where it inhibits an essential function by binding to polyanionic DNA (18, 26) . It has been argued that antimicrobial peptides provides organisms with molecules that are rapidly synthesized because of small size, less costly to synthesize than antibodies or specific phagocytic cells, and can be stored if necessary as processed biologicallyactive components which are rapidly available for host defense (2) . The ability of the antibacterial peptide to lyse cells is the result of a complex interrelationship of factors involving conformation, charge, hydrophobic and amphipathicity. The cationic residues in an antimicrobial peptide are considered to be important in the initial binding to the negatively charged phospholipids in the cell membranes of microorganisms (27) . It has been suggested that increasing the hydrophobic moment of an antimicrobial peptide has a relatively modest effect on the ability to make the microorganisms negatively-charged cell membrane permeable but not a marked effect on the more zwitterionic phospholipid membrane of the erythrocyte (26) . In general, although it is accepted that a polypeptide chain of at least 20 amino acids is necessary to span the membrane lipid bilayer to effect the formation of ion channels (14) , shorter cationic alpha-helical amphipathic peptides of 8-12 residues can also form ion channels, presumably through head-to-tail dimerization of the peptides (1). In a conventional assay on human RBC, whole venom caused significant hemolysis, but NAP did not cause a significant hemolysis. It was known that appearance of numerous contiguous apolar residues in a helix is necessary for a significant hemolysis to occur (17) . Like other antimicrobial peptides, the polar residues in the NAP might be well interspersed among the hydrophobic residues, interrupting the contiguity of hydrophobicity, which gives the potential to form an amphipathic helix. 
